CareLit · DOI-Nachweis · Pneumologie
Sensitivity analyses from the INPULSIS™ trials of nintedanib
DOI 10.1055/s-0035-1544833
Bibliografische Angaben
Nachweis in CareLit
Autor:innenC Neurohr, M Kolb, HR Collard, S Stowasser, M Girard, R Schlenker-Herceg, L Richeldi
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Nintedanib, an intracellular inhibitor of tyrosine kinases, is in development for the treatment of idiopathic pulmonary fibrosis (IPF). The INPULSIS™ trials were two replicate, 52-week, randomized, double-blind, placebo-controlled Phase III trials that investigated the efficacy and safety of nintedanib 150 mg twice daily in 1066 patients with IPF. The primary endpoint was the annual rate of decline in fo…
Zitieren
Zitierempfehlung
C Neurohr, M Kolb, HR Collard, S Stowasser, M Girard, R Schlenker-Herceg, L Richeldi (2015) Sensitivity analyses from the INPULSIS™ trials of nintedanib. Pneumologie (02). https://doi.org/10.1055/s-0035-1544833
Mit CareLit weiterarbeiten